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Abstract
Dengue is the most prevalent arthropod-borne viral illness in humans. A MHC class I polypeptide-related sequence B (MICB)
single nucleotide polymorphism (SNP) was previously associated with symptomatic dengue compared to non-dengue
causes of acute febrile illnesses in infants. We measured circulating levels of soluble (s)MICB in the sera of infants with
symptomatic primary dengue virus infections. We found that serum levels of sMICB increased between pre-infection and
acute illness among infants with symptomatic primary dengue virus infections. The likelihood of being hospitalized with an
acute primary DENV infection during infancy also tended to be higher with increasing acute illness sMICB levels. The
elevation of sMICB during acute primary DENV infections in infants likely represents an immune evasion strategy and
contributes to the severity of the acute illness.
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Introduction
Dengue is the most prevalent arthropod-borne viral illness in
humans with half of the world’s population at risk. The global
burden of symptomatic dengue is on the order of 100 million
cases/year [1]. The dengue viruses (DENVs) are single-stranded,
positive-sense, RNA-containing enveloped viruses belonging to the
Flavivirus genus within the Flaviviridae family [2]. There are four
serotypes of DENVs (DENV1-4). DENV infections produce a
wide spectrum of clinical illness. It ranges from asymptomatic or
mild illness to a severe and potentially life threatening disease,
dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS).
A genome-wide association study (GWAS) found that polymor-
phisms in only two genes were associated with the development of
DSS compared to milder forms of symptomatic dengue in children
and adults [3]. One of those genes was MHC class I polypeptide-
related sequence B (MICB). The MICB single nucleotide
polymorphism (SNP) rs3132468 was also associated with symp-
tomatic dengue compared to non-dengue causes of acute febrile
illnesses in children and adults, and in infants [4]. Proteolytic
cleavage of MICB on cell surface membranes produces soluble
(s)MICB that can be measured in sera [5]. We have been
conducting a prospective clinical study of DENV infections during
infancy in the Philippines [6]. We therefore examined circulating
levels of sMICB in the sera of infants with symptomatic primary
dengue virus infections. We found that serum levels of sMICB
increased between pre-infection and acute illness among infants
with symptomatic primary dengue virus infections. The likelihood
of being hospitalized with an acute primary DENV infection
during infancy also tended to be higher with increasing acute
illness sMICB levels.
Methods
Ethics Statement
The study protocol was approved by the institutional review
boards of the Research Institute for Tropical Medicine, Philip-
pines, and the University of Massachusetts Medical School.
Mothers and their healthy infants were recruited and enrolled
after providing written informed consent.
Clinical Study
The study began in January 2007 in San Pablo, Laguna,
Philippines, and has been previously described [6]. Blood samples
were collected from the infant and mother at the first study visit
when the infant was between approximately 6-18 weeks old.
Clinical and epidemiological information were collected at the
study visit. We conducted surveillance year-round for hospitalized
acute febrile illnesses in study infants across the seven hospitals
serving San Pablo, Philippines. During the rainy season (June-
November), mothers were encouraged to bring their infants to the
San Pablo City Health Office for evaluation of outpatient febrile
illnesses. Acute- and convalescent-phase (day 14) blood samples
were obtained from study infants with febrile illnesses that did not
have an obvious source at time of presentation (e.g. lobar
pneumonia, bacterial meningitis, pyelonephritis).
A DENV infection was identified in febrile infants by serotype-
specific RT-PCR in acute-phase sera and DENV IgM/IgG
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ELISA in paired acute and convalescent phase sera. Primary or
secondary DENV infections were identified by previously estab-
lished serologic criteria for the paired IgM/IgG ELISA results [7].
The infecting DENV serotype was identified by RT-PCR for all
the symptomatic infants.
sMICB ELISA
Briefly, capture Ab to human MICB (R&D Systems, 20 mg/ml)
was coated on 96-well flat-bottomed microtiter plates (Thermo
Scientific). Plates were blocked with bovine serum albumin (BSA).
Undiluted sera (50 ml/well) were added to the plates and
incubated for 2 h at room temperature. Then, biotin-conjugated
detecting Ab to human MICB (R&D Systems, 2 mg/ml) was
added followed by streptavidin-horseradish peroxidase (HRP).
The ELISA plates were developed using SuperSignal ELISA
Femto Substrate (Pierce Protein Biology). sMICB levels were
determined using a luminometer (Envision 2012 plate reader,
Perkin Elmer).
Statistical Analysis
The SPSS software package (version 21.0) was used for
statistical analyses. Comparisons between pre-infection and acute
illness paired sMICB levels were made using the Wilcoxon signed
rank non-parametric statistical test. P,0.05 was considered
significant; 0.05#p,0.10 was considered a significant trend.
Results
Symptomatic primary DENV infections in infants
The characteristics of the infants with symptomatic primary
DENV infections are shown in Table 1.
Circulating levels of sMICB in infants with symptomatic
primary DENV infections
Circulating levels of sMICB increased between the pre-infection
levels at study visit 1 and acute illness levels among infants with
symptomatic primary DENV infections (Figure 1). sMICB levels
were not different over the first week of illness among infants with
symptomatic primary DENV infections (Figure 2).
sMICB levels trend higher in infants hospitalized with
primary DENV infections
In a binary logistic regression model, the odds of a symptomatic
primary DENV infection during infancy that led to hospitalization
trended higher for every 100 pg/ml increase in acute illness serum
Table 1. Characteristics of infants with symptomatic primary dengue virus (DENV) infections.
Number of infants n=46
Age at time of DENV infection (median [95% confidence interval]) 7.4 [5.8–8.6] months
Gender (male:female) 23:23
Serotype of dengue virus infection DENV1: n=5 DENV2: n= 6 DENV3: n= 33 DENV4: n=2
Disease severity Hospitalized: n=24 Outpatient: n= 22
doi:10.1371/journal.pone.0098509.t001
Figure 1. Serum levels of soluble (s)MICB pre-infection and during acute illness among infants with symptomatic primary dengue
virus infections (n=46). Ages are shown as median [95% confidence interval]. Bars are median values. * p,0.001 for comparison between the two
groups.
doi:10.1371/journal.pone.0098509.g001
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sMICB (odds ratio (OR) [95% confidence interval] for hospital-
ization compared to outpatient illness: 1.4 [0.97–2.1], p = 0.075,
n=46).
Discussion
MICB is a cell surface protein and a ligand for the natural killer
group 2 member D (NKG2D) receptor, a stimulatory receptor on
NK cells and a co-stimulatory receptor on CD8+ T-cells [8].
sMICB blocks the activating signal produced by MICB-NKG2D,
and is felt to be an immune evasion strategy [5]. We found that
circulating levels of sMICB increased during acute primary
symptomatic DENV infections in infants compared to pre-
infection levels. The elevation of sMICB during acute DENV
infections is likely an immune evasion strategy in a systemic viral
infection. It could inhibit activation of the anti-viral effects of NK
cells, CD8+ T-cells, or both, in infants with primary DENV
infections and thereby contribute to the development of an acute
febrile illness. We also noted that the circulating levels of sMICB in
healthy 2 month old infants were higher than what has been
reported in healthy adults [9,10]. This may contribute to the
susceptibility of infants to severe dengue with primary infections.
The likelihood of being hospitalized with an acute primary
DENV infection during infancy tended to be higher with
increasing acute illness sMICB levels. The MICB polymorphism
(MICB SNP rs3132468) associated with symptomatic dengue in
infants is an A/G change in an intron region of the human MICB
gene (dbSNP database, NCBI). The effect of this SNP is unknown,
but we postulate it could promote the proteolytic cleavage of cell
surface MICB leading to increased sMICB levels. Further
experiments to examine the effect of this SNP are planned.
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Figure 2. Serum levels of soluble (s)MICB during acute illness by day of fever among infants with symptomatic primary dengue
virus infections (n=46).
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